Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Franzetti, Marco ^a   Violin, Michela ^a   Antinori, Andrea ^b   De Luca, Andrea ^c   Ceccherini Silberstein, Francesca ^d   Gianotti, Nicola ^e   Torti, Carlo ^f,g   Bonora, Stefano ^h   Zazzi, Maurizio ⁱ   Balotta, Claudia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

Author keywords

Antiretroviral therapy; HIV; HIV acquired resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; THYMIDINE DERIVATIVE; TIPRANAVIR;

ADULT; ARTICLE; DATA BASE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ITALY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; VIREMIA; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 84904275261     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-398     Document Type: Article

References (36)

1. Mocroft A, Ledergerber B, Katlama, Kirk O, Reiss P, D'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, . EuroSIDA study group Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29. EuroSIDA study group.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
3. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005, 19:1081-1089.
4. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002, 15:247-277.
5. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004, 18:1393-1401.
6. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003, 17:2383-2388.
7. Scott P, Arnold E, Evans B, Pozniak A, Moyle G, Shahmenesh M, White D, Shirley J, Cane P, Pillay D. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004, 53:469-473.
8. Lohse N, Obel N, Kronborg G, Jørgensen LB, Pedersen C, Larsen CS, Kvinesdal B, Sørensen HT, Gerstoft J. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006, 11:591-600.
9. WHO, UNAIDS and UNICEF Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions In The Health Sector. Progress Report 2009. 2009, Geneva: World Health Organization, [http://www.who.int/hiv/pub/tuapr_2009_en.pdf], WHO, UNAIDS and UNICEF.
10. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010, 201:106-113.
11. Blower SM. Transmission of zidovudine resistant strains of HIV-1: the first wave. AIDS 2001, 15:2317-2318.
12. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, . EuroCoord-CHAIN study group Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011, 11:363-371. EuroCoord-CHAIN study group.
13. Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C, . UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD) The impact of HIV drug resistance testing on changes to treatment. AIDS 2011, 25:603-610. UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD).
14. Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005, 192:967-973.
15. Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, Bacheler L. Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals. J Clin Virol 2009, 44:190-194.
16. De Mendoza C, Garrido C, Corral A, Ramírez-Olivencia G, Jiménez-Nacher I, Zahonero N, Gonzalez-Lahoz J, Soriano V. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 2007, 23:879-885.
17. Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 2009, 14:359-369.
18. Di Giambenedetto S, Prosperi M, Fanti I, Bruzzone B, Paolucci S, Penco G, Meini G, Di Biagio A, Paolini E, Micheli V, Meraviglia P, Castelli P, Corsi P, Gonnelli A, Fabbiani M, Zazzi M, De Luca A. Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. Clin Microbiol Infect 2011, 17:1352-1355.
19. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines For The Use Of Antiretroviral Agents In Hiv-1-Infected Adults And Adolescents. Department of Health and Human Services, Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents.
20. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013, 21:6-14.
21. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis 2013, 207:1216-1220.
22. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, Vandamme AM, Camacho R. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008, 5:12-16.
23. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.
24. Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008, 22:367-376.
25. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010, 54:4253-4261.
26. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, Jacobson LP. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007, 45:1377-1385.
27. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 2009, 23:1035-1046.
28. Mackie NE, Philis AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. JID 2010, 201:1303-1307.
29. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010, 44:157-165.
30. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008, 47:161-167.
31. Ross L, Vavro C, Wine B, Liao Q. Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin Trials 2006, 7:334-338.
32. Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother 2012, 67:1475-1478.
33. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009, 51:163-174.
34. Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010, 24:87-96.
35. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings. PLoS Med 2012, 9:e1001290.
36. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, Manca N, Penco G, Bruzzone B, Punzi G, Corsi P, Parruti G, Bagnarelli P, Monno L, Gonnelli A, Cauda R, Di Giambenedetto S. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect 2012, 18:E299-E304.